Beyond surgery: bladder preservation and the role of systemic treatment in localised muscle-invasive bladder cancer

World J Urol. 2024 Apr 4;42(1):210. doi: 10.1007/s00345-024-04892-8.

Abstract

Over the last two to three decades the non-surgical curative management of bladder cancer has significantly progressed. Increasing evidence supports the use of bladder preservation as an alternative to radical cystectomy (RC) for localised muscle-invasive bladder cancer (MIBC). Radiosensitisation with chemotherapy or hypoxia modification improves the efficacy of radiotherapy. Systemic treatments play an important role in the management of localised MIBC with the benefit of neoadjuvant chemotherapy prior to radical treatment well established. The use of immune checkpoint inhibitors (ICIs) in the radical treatment of bladder cancer, their safe combination with radical radiotherapy regimens and whether the addition of ICIs improve rates of cure are outstanding questions beginning to be answered by ongoing clinical trials. In this narrative review, we discuss the current evidence for bladder preservation and the role of systemic treatments for localised MIBC.

Keywords: Bladder cancer; Bladder preservation; Hypoxia; Immunotherapy.

Publication types

  • Review

MeSH terms

  • Cystectomy
  • Humans
  • Immune Checkpoint Inhibitors
  • Muscles
  • Urinary Bladder Neoplasms* / drug therapy
  • Urinary Bladder Neoplasms* / surgery
  • Urinary Bladder* / surgery

Substances

  • Immune Checkpoint Inhibitors